Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer

Clinical Colorectal Cancer

Volumn 12, Issue 1, 2013, Pages 54-61

  Kornmann, Marko ^a   Staib, Ludger ^b   Wiegel, Thomas ^a   Kron, Martina ^a   Henne Bruns, Doris ^a   Link, Karl Heinrich ^b   Formentini, Andrea ^a  

^a UNIVERSITY OF ULM   (Germany)

^b Study Group Oncology of Gastrointestinal Tumors (FOGT)   (Germany)

Author keywords

5 Fluorouracil; Adjuvant treatment; Colon cancer; Rectal cancer; Recurrence

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL EVALUATION; COLON CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PROSPECTIVE STUDY; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM ANTERIOR RESECTION; RECTUM CANCER; SURVIVAL RATE; TREATMENT DURATION;

EID: 84874673961     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2012.07.005     Document Type: Article

References (30)

1. D. Cunningham, W. Atkin, H.J. Lenz Colorectal cancer Lancet 375 2010 1030 1047
2. D.G. Haller, P.J. Catalano, J.S. Macdonald Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089 J Clin Oncol 23 2005 8671 8678
3. K.H. Link, M. Kornmann, L. Staib Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha Ann Surg 242 2005 178 187
4. E. Van Cutsem, J. Oliveira Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up Ann Oncol 20 suppl 4 2009 49 50
5. W. Schmiegel, C. Pox, A. Reinacher-Schick S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII) Z Gastroenterol 48 2010 65 136
6. R. Sauer, H. Becker, W. Hohenberger Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 2004 1731 1740
7. J.F. Bosset, L. Collette, G. Calais Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med 355 2006 1114 1123
8. A.L. Martling, T. Holm, L.E. Rutqvist Effect of a surgical training programme on outcome of rectal cancer in the county of Stockholm Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project Lancet 356 2000 93 96
9. A. Wibe, B. Møller, J. Norstein A national strategic change in treatment policy for rectal cancer - implementation of total mesorectal excision as routine treatment in Norway A national audit Dis Colon Rectum 45 2002 857 866
10. K.C. Peeters, C.A. Marijnen, I.D. Nagtegaal The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma Ann Surg 246 2007 693 701
11. M. Kornmann, L. Staib, T. Wiegel Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α Br J Cancer 103 2010 1163 1172
12. N. Wolmark, H.S. Wieand, D.M. Hyams Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02 J Natl Cancer Inst 92 2000 388 396
13. J.E. Tepper, M. O'Connell, D. Niedzwiecki Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control-final report of intergroup 0114 J Clin Oncol 20 2002 1744 1750
14. O. Dahl, Ø. Fluge, E. Carlsen Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisole in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group Acta Oncol 48 2009 368 376
15. C. Herfahrt, P. Schlag Richtlinien zur operativen Therapie maligner Tumoren 1991 Karl Demeter Verlag Stuttgart
16. B. Glimelius, O. Dahl, B. Cedermark Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group Acta Oncol 44 2005 904 912
17. L. Collette, J.F. Bosset, M. den Dulk Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group J Clin Oncol 25 2007 4379 4386
18. S. Popat, A. Matakidou, R.S. Houlston Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis J Clin Oncol 22 2004 529 536
19. P.M. Wilson, R.D. Ladner, H.J. Lenz Predictive and prognostic markers in colorectal cancer Gastrointest Cancer Res 1 2007 237 246
20. W.L. Allen, P.G. Johnston Role of genomic markers in colorectal cancer treatment J Clin Oncol 23 2005 4545 4552
21. R. Gorlick, R. Metzger, K.D. Danenberg Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma J Clin Oncol 16 1998 1465 1469
22. H. Yamada, W. Ichikawa, H. Uetake Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites Clin Colorectal Cancer 1 2001 169 173
23. L. Staib, K.H. Link, A. Blatz Surgery of colorectal cancer: surgical morbidity and five- and ten-year results in 2400 patients - monoinstitutional experience World J Surg 26 2002 59 66
24. M. Kornmann, W. Schwabe, S. Sander Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil Clin Cancer Res 9 2003 4116 4124
25. M. Kornmann, A. Formentini, C. Ette Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment Eur J Surg Oncol 34 2008 1316 1321
26. R. Glynne-Jones, S. Mawdsley, M. Harrison Cetuximab and chemoradiation for rectal cancer - is the water getting muddy? Acta Oncol 49 2010 278 286
27. C. Weiss, D. Arnold, K. Dellas Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: a pooled analysis of three prospective phase I-II trials Int J Radiat Oncol Biol Phys 78 2010 472 478
28. C. Rödel, R. Sauer Integration of novel agents into combined-modality treatment for rectal cancer patients Strahlenther Onkol 183 2007 227 235
29. A. Martling, B. Cedermark, H. Johansson The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer Br J Surg 89 2002 1008 1013
30. M. den Dulk, H. Putter, L. Collette The abdominoperineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer Eur J Cancer 45 2009 1175 1183